卵巢癌原癌基因c－erbB－2扩增与预后的关系

提取卵巢癌组织ＤＮＡ，限制性内切酶ＥｃｏＲＩ酶解后，经过凝胶电泳，Ｓｏｕｔｈｅｒｎ转移至硝酸纤维膜，与￣（３２）Ｐ标记的ｃ－ｅｒｂＢ－２探针进行分子杂交，放射自显影。结果显示，２６例上皮性卵巢癌中，８例（３０．８％）出现了该基因的扩增。这８例均为晚期（ＩＩＩ～ＩＶ期）肿瘤病人，其中５例在术后２～４个月内死亡，说明该基因的扩增在晚期卵巢癌中出现，与病人预后不良有关，该基因的激活在卵巢癌的发生过程中亦起一定的作用。

The relation between prognosis and amplification ofthe C-erbB-2 (HER-2/neu) proto-oncogene in ovariancarcinomas

-erbB-2 (HER-2/neu) proto-oncogene is mainlyexpressed in epithelial tissue and activated due to itsamplification. Amplification of the C-erbB-2 proto-oncogene is associated with poor prognosis in humanovarian cancer. We exairJined whether arnplificationof C-erbB-2 is common in ovarian carcinoma or is as-sociated with poor prognosis. The DNA of ovariancarcinoma was extracted and consequently digestedwith restriction endonuclease EcoRI, electrophoresedin 0.8% agarose gels and blotted onto nitrocelluiosefilter with Southern transfering method. It was hy-bridized with a 32p-labelled C-erbB-2 probe and sub-sequently underwent autoradiography, It was shownthat the C-erbB-2 (HER-2/neu) gene was amplifiedin 8 of 26 human ovarian carcinornas (30.8%). Clin-ically the 8 patients with the amplified C-erbB-2 werein their advanced stage(III-IV). Five of the patientsdied from 2 to 4 months after operation. These find-ings sdggest that amplification of the C-erbB-2 geneniay play a role in the patnogenesis of ovarian carci-noma, it is frequently observed in advanced ovariancarcinoma and associated with poor prognosis forthese patients.